Navigation Links
An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes

inical Pharmacology (12.3).) Use with Medications Known to Cause Hypoglycemia: In clinical trials of JANUVIA as monotherapy and JANUVIA as part of combination therapy with metformin or pioglitazone, rates of hypoglycemia reported with JANUVIA were similar to rates in patients taking placebo. The use of JANUVIA in combination with medications known to cause hypoglycemia, such as sulfonylureas or insulin, has not been adequately studied. 6 ADVERSE REACTIONS Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. 6.1 Clinical Trials Experience In controlled clinical studies as both monotherapy and combination therapy, the overall incidence of adverse reactions with JANUVIA was similar to that reported with placebo. Discontinuation of therapy due to clinical adverse reactions was also similar to placebo. Two placebo-controlled monotherapy studies, one of 18- and one of 24-week duration, included patients treated with JANUVIA 100 mg daily, JANUVIA 200 mg daily, and placebo. Two 24-week, placebo-controlled combination studies, one with metformin and one with pioglitazone, were also conducted. In addition to a stable dose of metformin or pioglitazone, patients whose diabetes was not adequately controlled were given either JANUVIA 100 mg daily or placebo. The adverse reactions, reported regardless of investigator assessment of causality in greater than or equal to 5% of patients treated with JANUVIA 100 mg daily as monotherapy or in combination with pioglitazone and more commonly than in patients treated with placebo, are shown in Table 1. Table 1 Placebo-Controlled Clinical Studies of JANUVIA Monotherapy or Combination with Pioglitazone: Adverse R
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
3. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
4. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
5. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
6. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
10. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
11. Investigational Study Evaluates the Effectiveness of Aripiprazole in Adolescents With Schizophrenia
Post Your Comments:
(Date:7/31/2014)... , July 31, 2014 TB ... and developing better, faster and affordable treatments, announced ... Senior Vice President, External Affairs. Mr. Brock comes ... Head of Major Donor Relations for WWF International ... his role, Mr. Brock will guide the TB ...
(Date:7/31/2014)... und KISSING, Deutschland, 31. Juli ... und Distributor eines computerunterstützten („robotischen") Koloskopie-Systems für ... (Homi) Shamir , ein weltweit anerkannter Manager ... und Kontrollgremiums zum Unternehmen stößt. ... Shamir ist ein hochangesehener globaler Visionär ...
(Date:7/31/2014)... , July 31, 2014 Nutrastar International ... producer and supplier of premium branded consumer products, including ... and specialty foods, today announced the signing of its ... and its expansion to Hubei Province ... Central China . ...
Breaking Medicine Technology:TB Alliance Appoints Willo Brock Senior Vice President, External Affairs 2invendo medical holt Nachum (Homi) Shamir in den Board of Directors des Unternehmens 2invendo medical holt Nachum (Homi) Shamir in den Board of Directors des Unternehmens 3Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 2Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 3Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 4
... Feb. 9, 2011 Reportlinker.com announces that a ... catalogue: European Market for Dental ... http://www.reportlinker.com/p0377961/European-Market-for-Dental-Prosthetics-and-CAD/CAM-Devices-2011.html In 2010, ... crowns, bridges and dentures, were valued at over ...
... 2011 Protect Pharmaceutical Corporation (OTC Bulletin Board: ... of two patents and patents-applications to Grunenthal GmbH, a German ... discovery and research. The patent portfolio includes innovative pain drugs ... Ram Sesha, Protect,s Chief Operating Officer, said, "We are ...
Cached Medicine Technology:Reportlinker Adds European Market for Dental Prosthetics and CAD/CAM Devices 2011 2Protect Pharma Sells Patent Portfolio to Grunenthal GmbH 2
(Date:7/31/2014)... 31, 2014 Web Programming Services, a ... certified internet marketing firm, has recently launched a new ... this service affordable for everyone, the company has announced ... , Web Programming Services has tailored the service ... brochure designing and likely expectations of the clients from ...
(Date:7/31/2014)... By Randy Dotinga ... -- The parasite that causes malaria is growing increasingly resistant ... new surveillance reports. But several new drugs are in development, ... new hope against this global killer. "Although there has ... the battle against malaria is far from won, and there ...
(Date:7/31/2014)... -- Recovery time after surgery may be reduced for ... to a new study. The study,s Irish researchers ... response, reducing the amount of time surgical patients, wounds ... true among people who tend to have healing complications. ... prescribed medications in the world. While they are typically ...
(Date:7/31/2014)... India (PRWEB) July 31, 2014 ... launched a new online reputation management service named ... as well as organizations get rid of Pissed ... the result of extensive research. ReputationChief.Com management assigned ... service for those who are struggling in their ...
(Date:7/31/2014)... New Delhi, India (PRWEB) July 31, 2014 ... Certified Internet Marketing Company, has introduced a new ... quite affordable.     , Ethane Web Technologies has designed ... the expectations of clients and Java Development service ... has given the company a confidence to promise ...
Breaking Medicine News(10 mins):Health News:Web Programming Services Introduces Affordable Brochure Designing Service 2Health News:Malaria Growing Resistant to Drugs Used to Fight It 2Health News:Malaria Growing Resistant to Drugs Used to Fight It 3Health News:Cholesterol Drugs May Speed Healing After Surgery 2Health News:ReputationChief.Com Announces a New Online Reputation Management Service 2Health News:Ethane Web Technologies Announces Java Development Service at Pocket Friendly Cost 2
... Biosciences LLC, a Boston-based company conceived in partnership ... today that Johnson & Johnson has joined the ... will have the opportunity to invest in the ... to fundamentally transform drug discovery and development and ...
... Limited (Nasdaq: WCRX ) announced today that ... close on Tuesday, January 27, 2009. In addition to ... Executive Officer and Paul Herendeen, Executive Vice President and ... audio webcast to discuss the 2009 Financial Guidance for ...
... Keystone Symposium - Obesity: Novel Aspects of the Regulation ... Genetics, Inc. (NYSE Alternext US: ILI) announced today that ... role genetics play in an individual,s ability to lose ... during tomorrow,s Keystone Symposium titled, "Obesity: Novel Aspects of ...
... Blood Bank is honored to announce that it has ... of Cellular Therapy ("FACT"). CORD:USE is a leading ... processing, storage and distribution of donated cord blood. ... more than 14,000 patients with over 70 life-threatening diseases ...
... DIEGO, Jan. 22 Aero Financial, Inc, a strategic ... that the company has been retained as a strategic ... distributor of natural health information and nutrition products.Pursuant to ... Finest(TM) in several facets of the company,s growth plans, ...
... for 11:00 a.m. ET POWAY, Calif., Jan. 22 ... provider of diagnostic imaging products and services that improve ... before the market opens on Thursday, February 5, 2009, ... December 31, 2008. A conference call is scheduled for ...
Cached Medicine News:Health News:Enlight Biosciences Expands to direct up to $52 Million to Transformational Enabling Technologies 2Health News:Enlight Biosciences Expands to direct up to $52 Million to Transformational Enabling Technologies 3Health News:Interleukin Genetics to Present Data Highlighting Link Between Inflammatory Gene Variations and Less Effective Weightloss 2Health News:Interleukin Genetics to Present Data Highlighting Link Between Inflammatory Gene Variations and Less Effective Weightloss 3Health News:CORD:USE Cord Blood Bank Receives Prestigious Accreditation from the Foundation for the Accreditation of Cellular Therapy 2Health News:Aero Financial Retained as Strategic Consultant by Only Natures Finest(TM) 2Health News:Digirad Corporation to Release Fourth Quarter and Year-End Financial Results on February 5, 2009 2
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
Medicine Products: